The Effect of Buprenorphine Continuation for Patients With Opioid Use Disorder
Status:
Not yet recruiting
Trial end date:
2023-01-31
Target enrollment:
Participant gender:
Summary
There is limited guidance on the optimal management of buprenorphine perioperatively and both
buprenorphine discontinuation and continuation are acceptable standards of care. However,
there is the risk for opioid cravings and relapse when buprenorphine is discontinued.
Conversely, there is the risk of inadequate pain control necessitating opioid escalation in
when buprenorphine is continued. Preliminary clinical observations support buprenorphine
continuation at low analgesic doses (8mg) can adequately facilitate postoperative pain
management without interrupting opioid use disorder (OUD) treatment, however to date, no
prospective trial has investigated this treatment strategy in comparison to buprenorphine
discontinuation. Since optimal perioperative dosing strategies remain unknown, the purpose of
this study is to investigate if buprenorphine continuation at analgesic dosing is superior to
buprenorphine discontinuation in individuals presenting for elective surgery.